|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
389,580,000 |
Market
Cap: |
45.17(B) |
Last
Volume: |
1,813,692 |
Avg
Vol: |
1,929,144 |
52
Week Range: |
$75.49 - $140.45 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Health Services |
Level
III Sector: |
Medical Instruments & Supplies |
|
Member Indexes:
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 487 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile DexCom is a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems. Co.'s product candidates include Dexcom G7®, which is designed with the goal of carrying forward many of the same features as Co.'s G6 CGM system and adding several new or improved features. Co.'s products include: DexCom G6® integrated Continuous Glucose Monitoring System (G6), which is a type of CGM system to be used as part of an integrated system with other medical devices and electronic interfaces; and DexCom Share®, which transmit glucose information to the cloud and then to apps on the mobile devices of up to five designated recipients.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
64,005 |
267,979 |
302,595 |
574,627 |
Total Sell Value |
$8,769,441 |
$35,482,928 |
$39,449,301 |
$69,910,840 |
Total People Sold |
6 |
8 |
13 |
15 |
Total Sell Transactions |
10 |
24 |
47 |
82 |
End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Sayer Kevin R |
President, CEO & Chairman |
|
2018-11-12 |
4 |
AS |
$142.25 |
$1,634,284 |
D/D |
(11,161) |
320,837 |
|
- |
|
Sayer Kevin R |
President, CEO & Chairman |
|
2018-11-12 |
4 |
OE |
$4.58 |
$51,117 |
D/D |
11,161 |
331,998 |
|
- |
|
Ace Heather S |
SVP Human Resources |
|
2018-11-09 |
4 |
AS |
$145.91 |
$627,294 |
D/D |
(4,258) |
65,081 |
|
- |
|
Abbey Donald |
EVP, Quality & Regulatory Afrs |
|
2018-11-09 |
4 |
AS |
$147.62 |
$1,575,159 |
D/D |
(10,550) |
88,089 |
|
- |
|
Murphy Patrick Michael |
SVP, GC & Chief Compliance Off |
|
2018-11-09 |
4 |
AS |
$148.11 |
$59,244 |
D/D |
(400) |
30,508 |
|
- |
|
Doubleday Richard |
EVP, Chief Commercial Officer |
|
2018-10-23 |
4 |
AS |
$128.66 |
$223,466 |
I/I |
(1,736) |
17,358 |
|
- |
|
Pacelli Steven Robert |
EVP, Strategy & Corp. Dev. |
|
2018-10-23 |
4 |
AS |
$128.61 |
$401,253 |
D/D |
(3,114) |
110,746 |
|
- |
|
Balo Andrew K |
EVP, Reg. Strategy, Clinical |
|
2018-10-12 |
4 |
AS |
$124.49 |
$623,934 |
D/D |
(5,000) |
83,105 |
|
- |
|
Murphy Patrick Michael |
SVP, GC & Chief Compliance Off |
|
2018-10-10 |
4 |
AS |
$122.20 |
$48,880 |
D/D |
(400) |
30,908 |
|
- |
|
Sayer Kevin R |
President, CEO & Chairman |
|
2018-10-08 |
4 |
AS |
$124.32 |
$1,392,433 |
D/D |
(11,161) |
320,837 |
|
- |
|
Sayer Kevin R |
President, CEO & Chairman |
|
2018-10-08 |
4 |
OE |
$4.58 |
$51,117 |
D/D |
11,161 |
331,998 |
|
- |
|
Altman Steven R |
Director |
|
2018-10-01 |
4 |
AS |
$132.68 |
$339,134 |
I/I |
(2,500) |
55,355 |
|
- |
|
Leach Jacob Steven |
Chief Technology Officer |
|
2018-09-28 |
4 |
AS |
$142.96 |
$6,852,139 |
I/I |
(47,600) |
0 |
|
- |
|
Pacelli Steven Robert |
EVP, Strategy & Corp. Dev. |
|
2018-09-24 |
4 |
AS |
$138.69 |
$439,841 |
D/D |
(3,114) |
113,860 |
|
- |
|
Doubleday Richard |
EVP, Chief Commercial Officer |
|
2018-09-24 |
4 |
AS |
$138.25 |
$245,129 |
I/I |
(1,736) |
19,094 |
|
- |
|
Balo Andrew K |
EVP, Reg. Strategy, Clinical |
|
2018-09-14 |
4 |
AS |
$144.46 |
$725,851 |
D/D |
(5,000) |
88,105 |
|
- |
|
Leach Jacob Steven |
SVP, Research & Development |
|
2018-09-12 |
4 |
OE |
$5.92 |
$88,800 |
D/D |
15,000 |
109,284 |
|
- |
|
Blackford Quentin S. |
EVP, CFO, PFO & PAO |
|
2018-09-11 |
4 |
AS |
$145.23 |
$1,241,028 |
D/D |
(8,440) |
87,131 |
|
- |
|
Leach Jacob Steven |
SVP, Research & Development |
|
2018-09-10 |
4 |
S |
$143.76 |
$663,286 |
D/D |
(4,614) |
94,284 |
|
- |
|
Ace Heather S |
SVP Human Resources |
|
2018-09-10 |
4 |
S |
$143.76 |
$263,360 |
D/D |
(1,832) |
69,339 |
|
- |
|
Moy Jeffrey |
SVP, Operations |
|
2018-09-10 |
4 |
AS |
$143.35 |
$822,256 |
I/I |
(5,736) |
16,711 |
|
- |
|
Moy Jeffrey |
SVP, Operations |
|
2018-09-10 |
4 |
A |
$0.00 |
$0 |
I/I |
17,386 |
22,447 |
|
- |
|
Moy Jeffrey |
SVP, Operations |
|
2018-09-10 |
4 |
AS |
$0.00 |
$0 |
D/D |
(17,386) |
46,534 |
|
- |
|
Moy Jeffrey |
SVP, Operations |
|
2018-09-10 |
4 |
AS |
$143.76 |
$660,411 |
D/D |
(4,594) |
63,920 |
|
- |
|
Pacelli Steven Robert |
EVP, Strategy & Corp. Dev. |
|
2018-09-10 |
4 |
S |
$143.76 |
$788,210 |
D/D |
(5,483) |
116,974 |
|
- |
|
2306 Records found
|
|
Page 29 of 93 |
|
|